Promoting and Sustaining Italian Proteome Science


Milan - The Italian Proteome Society (IPSo) has been created in November 2003 as a tool for co-ordination, especially in Italy but in collaboration with other proteome societies in Europe and around the world. Founded by renowned Italian scientists the society has already acquired a large number of international sponsors and partners like Ciphergen, Bio-Rad and Chiron Vaccines as well as the British Electrophoresis Society and the Proteomics Group at Munich's Technical University.
IPSo's Aims
IPSo is a non-profit organization that aims to promote research and training in the field of proteome science in universities, in public research agencies, in industry, in hospitals, and in their research institutions as well as in all interested centers. Furthermore IPSo intends to sustain and promote teaching in all disciplines correlated with proteome science in universities, pre-university and post-university schools, and in any other suitable centre. It favours the development of technological innovation within the realm of the proteome science as well as the scientific communication by promoting and sustaining various collaboration forms among different laboratories at the national level, coupled to the organization of congresses and meetings.
For an efficient diffusion of proteome research, IPSo will establish a few laboratories for permanent education, with a possibility of official credits for the participants. These laboratories will have to be equipped not only with instruments for two-dimensional separations, but also with mass spectrometry facilities and bioinfor-matic instruments for protein identifi-cation in search engines and databases. Wherever possible, with limited-number participants, IPSo will aim at individual facilities with hands-on experimentation for each participant. Three of these labs will be created, located at strategic places from the North to the South of Italy.
Additionally, the Society aims at creating a capillary informatic network for establishing contacts among different laboratories dealing with similar research projects, so as to favour inter-laboratory cooperation and, whenever possible, the aggregation into larger research units. It is thus hoped to create greater opportunities among those consociated laboratories for access to public Italian and EU funding.
Finally, IPSo is born as a society representative of all scientific realities in the Italian territory, which will have full rights of expression within the society. This structure will be reinforced also with the creation of regional divisions which will have full freedom of disseminating proteomic science locally and aggregating regionally different scientific realities.
First Proteome Congress
IPSo will hold the First National Congress on Proteomics in Verona on May 27-29 (see EuroBiotechNews 4/04).
Antonucci Francesca, Campostrini Natascia,
Castagna Annalisa, Cecconi Daniela
Strada le Grazie 15, I-37134 Verona
Tel.: +39-045-802-7086
Fax: +39-045-802-7929



Milan – Everyone agrees that Italy is not Greece, but it is common wisdom that the country could also be doing better. Considering the meagre growth of the Italian economy in the last decade however, data fom the 2011 survey of...



Milan – Italian drugmaker Newron Pharmaceuticals S.p.A. and Merck Serono have broadened the scope of their 5-year-old collaboration on CNS drugs. In addition to the Parkinson’s treatment safinamide, under the terms of a new...



Milan/Berlin – Swiss-Italian biotech Philogen SpA has revoked its plan to sell a 23% stake worth EUR65.3m and go public on the Milan stock exchange this Friday. The move came after German Bayer HealthCare unexpectedly terminated...



Rome – The EUR2.5m ERC Advanced Grants are the Grammies of European science – not in the same league as a Nobel Prize, but still a lucrative honor. In the fourth round since 2007, the European Research Council awarded some a590m...



Modena/London – Researchers from Germany, Italy and the UK have identified a molecule that is key to the onset of addiction and also involved into memory formation (EMBO Journal, doi:10.1038/emboj.2010.279). According to results...



Genoa/Philadelphia — The inexpensive anti-gout drug allopurinol can counteract colorectal adenoma progression, according to data presented yesterday at the 9th Annual AACR Frontiers in Cancer Prevention Research Conference...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Job Advert


As a company at the leading edge of genomics, the focus at Illumina is research and development. We take our employees seriously. From colleagues to career path to meeting professional goals, we help you find opportunities to grow your career. more...


All videos

Stock list

All quotes


  • PAION (D)1.77 EUR63.89%
  • 4SC (D)2.95 EUR11.32%
  • BIONOR PHARMA (N)0.86 NOK8.86%


  • STENTYS (F)2.83 EUR-26.30%
  • KARO BIO (S)24.60 SEK-16.04%


  • VERONA PHARMA (UK)3.40 GBP23.6%
  • IXICO (UK)35.75 GBP21.2%
  • SERODUS (N)2.71 NOK15.8%


  • STENTYS (F)2.83 EUR-49.0%
  • BIONOR PHARMA (N)0.86 NOK-46.2%
  • MOLMED (I)0.24 EUR-35.1%


  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.60 SEK3053.8%
  • 4SC (D)2.95 EUR243.0%


  • BIOTEST (D)13.79 EUR-85.3%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 12.02.2016


All Events